CTOs on the Move

Sarepta Therapeutics

www.sareptatherapeutics.com

 
Sarepta Therapeutics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Sarepta Therapeutics raised $100M on 07/19/2017

Similar Companies

DermTech International

DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genome Sciences Centre

Genome Sciences Centre is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scifluor Life Sciences

SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics. The company is creating a portfolio of new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a range of therapeutic categories and disease areas including retinal disease, CNS disorders, fungal and bacterial infections and inflammatory disease.

Carmot Therapeutics

Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.

Pharmaessentia

PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in The United States and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking.